AHA 2024 - Marc Bonaca presents the results of a sub-study from the CLEAR Outcomes trial on the effects of bempedoic acid on adverse limb event in statin-intolerant patients with symptomatic peripheral artery disease (PAD).
advertisement
Bempedoic acid reduces adverse limb events in patients with PAD
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Marc Bonaca, MD is a cardiologist and vascular medicine specialist and is the executive director of CPC Clinical Research and CPC Community Health at the University of Colorado, Boulder, CO, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 21 November 2024
Recommended
Details
Presenters
Overview
AHA 2024 - Marc Bonaca presents the results of a sub-study from the CLEAR Outcomes trial on the effects of bempedoic acid on adverse limb event in statin-intolerant patients with symptomatic peripheral artery disease (PAD).
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Marc Bonaca, MD is a cardiologist and vascular medicine specialist and is the executive director of CPC Clinical Research and CPC Community Health at the University of Colorado, Boulder, CO, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 21 November 2024
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
CME/CE
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
0.25 credits
<p>Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy</p>
CME/CE
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
0.25 credits
<p>IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis</p>
CME/CE
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
1.00 credits
<p>Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies</p>
MinuteCE®
Chemotherapy Strategies for Metastatic PDAC
0.25 credits
<p>Chemotherapy Strategies for Metastatic PDAC</p>
MinuteCE®
Partnering with Patients: Building Effective Communication and Support in HF Care
0.75 credits
<p>Partnering with Patients: Building Effective Communication and Support in HF Care</p>
MinuteCE®
A Practical Guide to Prescribing in HF
0.75 credits
<p>A Practical Guide to Prescribing in HF</p>
MinuteCE®
Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA
1.25 credits
<p>Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA</p>
MinuteCE®
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
0.75 credits
<p><span data-contrast="none" style="list-style-type: disc;" xml:lang="EN-US">The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC</span></p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?